Skip to content

A Study on the Safety and Effectiveness of Tenofovir, Lamivudine, and Dolutegravir (TLD) Treatment in Newly Diagnosed HIV Patients

TO STUDY THE EFFICACY AND SAFETY OF THE TENOFOVIR, LAMIVUDINE & DOLUTEGRAVIR (TLD) REGIMEN BY ASSESSING HEMATOLOGICAL AND BIOCHEMICAL PARAMETERS IN NEWLY DIAGNOSED HIV PATIENTS: A PROSPECTIVE OBSERVATIONAL STUDY - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/07/091910
Enrollment
190
Registered
2025-07-28
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B20- Human immunodeficiency virus [HIV]disease

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

Shri Atal Bihari Vajpayee Medical College and Research Institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Newly diagnosed HIV patients aged more than 18 years initiated on TLD therapy 2.Patients providing informed consent for participation.

Exclusion criteria

Exclusion criteria: 1. Patients with abnormal Liver function tests, Renal function tests, Lipid profiles and all types of Anaemia (IDA, Megaloblastic anaemia etc.) which may have confounding factors that affect the interpretation of Hematological and Biochemical parameters 2. Pregnant or lactating women. 3. Patients diagnosed with any co-morbid conditions such as diabetes mellitus, hypertension, tuberculosis, hepatitis B or C, chronic kidney disease, or any other condition.

Design outcomes

Primary

MeasureTime frame
Change in hematological and biochemical parameters over time in newly diagnosed HIV patients receiving TLD regimen.Timepoint: 1. At Baseline 2. At 3 months 3. At 6 months

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr GAJENDRA G

Shri Atal Bihari Vajpayee Medical College and Research Institute

nagu728@gmail.com9972279046

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026